Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]FLT PET/CT Imaging in Rb+ Metastatic Breast Cancer Patients Undergoing Ribociclib and Paclitaxel
NCT02608216Phase 1Active, not recruiting
- Sponsor
- University of Pennsylvania
- Start
- Nov 2015
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluorothymidine F-18 in breast cancer, sponsored by University of Pennsylvania. Primary endpoint: Changes in [18F]FLT uptake in metastatic tumors before and during treatment with ribociclib. Started Nov 2015; status: active, not recruiting.
02
Drugs
fluorothymidine F-18
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02608216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02608216.